First pass effect

Factors

First-pass metabolism may occur in the liver (for propranolol, lidocaine, clomethiazole, and nitroglycerin) or in the gut (for benzylpenicillin and insulin). The four primary systems that affect the first pass effect of a drug are the enzymes of the gastrointestinal lumen, gastrointestinal wall enzymes, bacterial enzymes and hepatic enzymes.

Hepatic first-pass

After a water-soluble drug is swallowed, it is absorbed by the digestive system and enters the hepatic portal system. It is carried through the portal vein into the liver before it reaches the rest of the body. The liver metabolizes many drugs, sometimes to such an extent that only a small amount of active drug emerges from the liver to the rest of the circulatory system. This first pass through the liver thus may greatly reduce the bioavailability of the drug.

An example of a drug where first-pass metabolism is a complication and disadvantage is in the antiviral drug remdesivir. Remdesivir cannot be administered orally because the entire dose would be trapped in the liver with little achieving systemic circulation or reaching target organs and cells (for example, cells infected with SARS-CoV-2). For this reason, remdesivir is administered by IV infusion, bypassing the portal vein. However, significant hepatic extraction still occurs because of second pass metabolism, whereby a fraction of venous blood travels through the hepatic portal vein and hepatocytes.

Drug design

In drug design, drug candidates may have good druglikeness but fail on first-pass metabolism because it is biochemically selective. Physiologically based pharmacokinetic models (PBPK) are used to predict first-pass metabolism, although they require compound-specific adjustments due to variability in intestinal mucosal permeability and other factors. Enzyme expression also varies between individuals, which may influence the efficiency of first-pass metabolism and thus the bioavailability of the drug.

Cytochromes P450, especially CYP3A4, play a crucial role in first-pass metabolism, affecting the bioavailability of drugs.

Mitigation

Converting a drug into a prodrug can help avoid first-pass metabolism, thereby improving its bioavailability. In vitro models, such as the use of microfluidic chips that simulate the gut and liver, allow first-pass metabolism to be studied more accurately, facilitating the development of drugs with better absorption profiles.

Routes of administration

Alternative routes of administration, such as insufflation, rectal administration, intravenous, intramuscular, inhalational aerosol, transdermal, or sublingual, avoid or partially avoid the first pass effect because they allow drugs to be absorbed directly into the systemic circulation.

Drugs with high first pass effect typically have a considerably higher oral dose than sublingual or parenteral dose. There is marked individual variation in the oral dose due to differences in the extent of first-pass metabolism, frequently among several other factors. Oral bioavailability of many vulnerable drugs appears to be increased in patients with compromised liver function. Bioavailability is also increased if another drug competing for first-pass metabolism enzymes is given concurrently (e.g., propranolol and chlorpromazine).

References

References

1. (January 1972). "Influence of route of administration on drug availability". Journal of Pharmaceutical Sciences.
2. (January 1984). "First-Pass Elimination". Clinical Pharmacokinetics.
3. Carlin, Michelle G.. (2023-01-01). "Pharmacology and Mechanism of Action of Drugs". Elsevier.
4. Bath-Hextall, Fiona. (October 16, 2013). "Understanding First Pass Metabolism". University of Nottingham.
5. (1990-01-01). "Mebolism of drugs and other xenobiotics in the gut lumen and wall". Pharmacology & Therapeutics.
6. (1997-09-15). "Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction". Advanced Drug Delivery Reviews.
7. (2018). "Protein Abundance of Clinically Relevant Drug-Metabolizing Enzymes in the Human Liver and Intestine: A Comparative Analysis in Paired Tissue Specimens". Clinical Pharmacology & Therapeutics.
8. (2002-04-01). "The Mucosa of the Small Intestine". Clinical Pharmacokinetics.
9. (1993). "Gastrointestinal and hepatic first-pass elimination of 2',3'-dideoxyinosine in rats". The Journal of Pharmacology and Experimental Therapeutics.
10. (2020). "Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment". ACS Medicinal Chemistry Letters.
11. "Fact sheet for health care providers Emergency Use Authorization (EUA) of Veklury®(remdesivir)".
12. (2025). "PBPK modeling: What is the role of CYP3A4 expression in the gastrointestinal tract to accurately predict first-pass metabolism?". CPT: Pharmacometrics & Systems Pharmacology.
13. (2012-09-29). "Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates – An evaluation and case study using GastroPlus™". European Journal of Pharmaceutical Sciences.
14. (2010). "Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data". Drug Metabolism and Disposition.
15. (2016-05-01). "Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination". The AAPS Journal.
16. (2018-01-01). "Chapter 8 - First-Pass Metabolism Considerations in Pharmaceutical Product Development". Academic Press.
17. (2021). "Recapitulation of First Pass Metabolism Using 3D Printed Microfluidic Chip and Organoid". Cells.
18. (2017-11-07). "3D gut-liver chip with a PK model for prediction of first-pass metabolism". Biomedical Microdevices.
19. (2017-01-10). "Microfluidic Gut-liver chip for reproducing the first pass metabolism". Biomedical Microdevices.
20. (1997-11-10). "Hepatic first-pass effect and controlled drug delivery following rectal administration". Advanced Drug Delivery Reviews.
21. (2022). "Aulton's Pharmaceutics: the design and manufacture of medicines". Elsevier Health Sciences.
22. (2009). "Non-invasive Systemic Drug Delivery: Developability Considerations for Alternate Routes of Administration". Journal of Pharmaceutical Sciences.